Moderna announces first participant dosed in phase 1 study of its mrna epstein-barr virus (ebv) vaccine

Moderna expects to enroll approximately 270 participants in the u.s. ebv is a major cause of infectious mononucleosis, which can debilitate patients for weeks to months; there is no approved vaccine to prevent ebv ebv can also lead to lifelong medical conditions and is associated with an increased risk of developing multiple sclerosis, certain lymphoproliferative disorders, cancers, and autoimmune diseases moderna now has a portfolio of two vaccines against latent viruses in the clinic: cmv and ebv cambridge, ma / accesswire / january 5, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced the first participant has been dosed in the phase 1 study of mrna-1189, the company's epstein-barr virus (ebv) vaccine candidate. the study is known as eclipse.
MRNA Ratings Summary
MRNA Quant Ranking